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Abstract 
Purpose: Support from family and other social network elements can be important in helping patients to cope with 
practical and emotional consequences of diseases. The aim of the study was to examine perception of family and 
social support and quality of life (QoL) in patients undergoing treatment for substance use disorders (SUDs). We com‑
pared them with patients in treatment for mental disorders (MDs) and physical disorders (PDs).
Methods: We used data from a national multicenter study that recruited patients (N  =  518) from three treatment 
domains; SUD treatment units, MD treatment units, and PD treatment units (severe neurological conditions or cancer). 
Data on family cohesion, social support, and QoL were compared across patient groups. In addition, data on health 
variables was collected. We used a multiple linear regression procedure to examine how health and support variables 
were associated with QoL.
Results: Family cohesion and social support in the SUD and MD groups were rated at similarly low levels, sub‑
stantially lower than in the PD group. The SUD group exhibited a somewhat lower QoL than did the PD group, but 
their QoL was still in the near‑to‑normal range. In contrast, the MD group had markedly low QoL. When examining 
factors associated with QoL, we found that greater family cohesion and social support were positively associated 
with QoL. Mental distress was the strongest factor, and was negatively associated with QoL (beta − 0.15, 95% CI  =  
− 0.17/− 0.14, p  <  0.001).
Conclusion: Service providers need to be aware of the weaker networks and less regulatory family and/or social 
support available to patients with SUDs. Providers should focus consistently on the social networks of patients and 
include patients’ families in treatment processes.
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Background
A substance use disorder (SUD) can be a serious clini-
cal condition causing major health problems and 
affecting a wide range of life domains [1, 2]. In times 
of illness, the family is a primary source of support 
for patients [3, 4]. This support includes facilitating 
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patients’ adaptation to living with the illness, improv-
ing their compliance with treatment, and in that way 
promoting recovery [5]. Thus, family cohesion has been 
considered a buffer against drinking and substance use, 
and a significant protective factor of substance abuse 
relapse among populations with such problems [6, 7]. 
Conversely, poor levels of family cohesion are related to 
greater levels of drinking and substance use [8]. How-
ever, when an SUD exists within a family, there is a 
risk that the strain the family experiences will lead to 
exhaustion or broken relationships [9, 10]. Efforts to 
support the family in order to enhance cohesion among 
family members, would thus seem beneficial both to 
the patient and to the family as a whole [7, 11]. Support 
from networks beyond the family (e.g., peer support, 
support groups, self-help groups) may be an additional 
resource to help patients cope with practical and emo-
tional consequences, as well as in maintaining remis-
sion [12, 13]. Higher level of social support, defined as 
being socially connected [14], has been associated with 
reduction of substance use and improved mental health 
for persons experiencing an SUD [15–17].
The aim of the present study was to examine patients’ 
own perception of family cohesion and social support. To 
put findings from the SUD treatment field into perspec-
tive, we compared SUD patients with patients from two 
other patient groups: those with mental disorders (MDs) 
and those with physical disorders (PDs). Family cohesion 
and social support are relevant to recovery, as described 
above, and we are not aware of any study that has exam-
ined these support factors across several patient groups 
including patients with SUDs. The rationale for the com-
parison was that family cohesion and social support 
is said to be equally important for patients with MDs. 
Stronger network support has the potential to reduce 
relapse and hospital admissions, encourage compliance 
with medication and, of direct relevance here, to reduce 
social impairment and improve general functioning [18, 
19]. Positive change in perceived social support is recog-
nized as a mediator of change in subsequent depressive 
and anxious symptomatology, and a higher level of social 
support has been associated with symptom reduction in 
patients with MDs [19, 20]. Thus, lack of family cohesion 
and social support would make patients with MDs and 
SUDs vulnerable in the recovery phase. Due to the often 
sudden onset of physical problems (e.g., cancer diagno-
sis) we considered the PD group likely to resemble more 
those of the general population in terms of the famil-
ial and social situation. We hypothesized that patients 
admitted to SUD treatment units would rate family cohe-
sion and general social support at least as low as the MD 
group and considerably lower than those admitted to PD 
treatment units.
As a main dependent or “outcome” variable in our 
analyses, we used the concept of quality of life (QoL); 
an overarching construct of health and well-being, 
considered to be a general aim across different patient 
groups and disorders [21, 22]. Thus, we aimed to 
examine how support variables were associated with 
QoL across patient groups. Among people experienc-
ing an SUD, studies have reported significantly lower 
QoL compared with the general population [23]. Fur-
thermore, substance abuse and/or mental distress is 
associated with low QoL [9, 24, 25]. For the present 
analysis, we expected that the SUD and MD groups 
would exhibit the lowest QoL and that greater family 
cohesion and social support would be positively associ-
ated with QoL.
Methods
Design, study setting, participants and procedures
This study used data from a cross-sectional, multicenter 
study, conducted in five Norwegian hospitals, in which 
the overall objective was to explore the experience of 
children when one of their parents had an illness, as 
well as the family’s perceived need for support [26]. In 
accordance with the overall aim of the study, the inclu-
sion criteria was that the patient provided parental care 
for children under age 18. We approached patients in 
three illness domains within the Norwegian special-
ist health care services and recruited 129 in SUD treat-
ment units, 194 in MD units, and 195 in PD units (severe 
neurological conditions or cancer). There were no exclu-
sion criteria other than not being able to understand the 
Norwegian language to complete the questionnaire. The 
present study examined the patients’ own perception of 
family cohesion and social support, as the patient gave 
information about their family situation, and reported on 
their own health and life situation. Data collection took 
place from March 2013 to December 2014. Trained per-
sonnel such as health care or social workers recruited 
patients and collected the data. The data collection took 
place according to participants’ choice, usually at their 
home. The data were collected on digital tablets and the 
total questionnaires required about 1 h to complete. The 
digital data strategy ensured that questionnaires were 
completed in full.
Measures
Basic demographic variables were collected, including 
age, gender, education, income, and occupation status. 
Occupation was defined as any positive occupational 
activity and included full-time and part-time occupations 
or ongoing education.
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Family and social variables
Data was collected about partner status, that is, whether 
patients were living alone or with a partner. To assess 
family support, we used the Family Cohesion Subscale in 
the Family Adaptability and Cohesion Evaluation Scales 
(FACES-III). The scale assesses the emotional bonding 
family members have towards one another and the per-
ceived connectedness within the family and, as such, it 
serves as a proxy for measuring emotional support in a 
family [27, 28]. The instrument consists of 10 statements, 
for example, “family members ask each other for help”, 
and were rated on ordinal scales from 1 (almost never) 
to 5 (almost always). The sum score ranged from 10 to 50 
and higher scores indicated higher perceived cohesion. 
The Interpersonal Support Evaluation List (ISEL) was 
used to measure the perceived availability of social sup-
port [29]. ISEL has 12 statements about social support 
rated on an ordinal scale (e.g., “I feel that there is no one I 
can share my most private worries and fears with”), with 
responses ranging from 1 to 4 (“definitely true”, probably 
true”, “probably false”, and “definitely false”). Ratings of 
positively worded items were reversed and a higher score 
indicated a more positive evaluation of social support. 
The sum score of the scale ranged from 12 to 48.
Health and treatment variables
We used an adapted version of the CAGE-AID (including 
both alcohol and drugs), to assess the lifetime prevalence 
of substance use problems [30]. A sum score based on 
four questions was calculated (range 0–4) and a score  ≥ 
2 was the cut-off for a substance use problem. The Hop-
kins Symptom Checklist (HSCL-10) was used to assess 
mental distress [31]. Patients rated the ten items on a 
4-point scale (1–4) and an average was computed to indi-
cate a global severity index (GSI). Higher scores indicate 
greater distress and the cut-off point for pathology was 
1.85. The illness was described with questions about ill-
ness duration (years since illness debut) and perceived 
prognosis, that is, whether there was uncertainty about 
how the illness would develop in the future. We also col-
lected information about treatment duration for the cur-
rent condition.
Quality of life
We used the QoL-5 to assess QoL. The QoL-5 is a non-
disease-specific scale, suitable for assessing QoL across 
different treatment domains. Patients rated their per-
ceived physical and mental health, and social situation, 
that is, their relationships with their partner and friends, 
and relationship with themselves, described as existen-
tial QoL by the developers [32]. Responses were scored 
on a 5-step ordinal scale from 1 to 5 and transposed to a 
decimal scale ranging from 0.1 to 0.9, where 0.9 was the 
best and 0.1 was the worst possible rating [33]. The mean 
score of the scale is an expression of global QoL. Norma-
tive data from a Danish general population survey indi-
cated that the general population norm was a mean score 
of 0.69 [34]. Population norms for each item on the scale 
do not exist, but the overall norm (~  0.7) has been used 
in previous research [23]. A score  ~  0.15 below that of 
the general population has been suggested to represent a 
clinically significant reduction in QoL, and scores below 
this cut-off (i.e.,  <  0.55) represent a markedly reduced 
QoL [35]. The internal consistency of the scale is good; 
the composite reliability coefficient was 0.87 in previous 
research [36].
Statistics
We used descriptive statistics to present socio-demo-
graphic variables. Differences between groups in fam-
ily, social, and health variables were examined using the 
chi-square test for categorical variables and ANOVA for 
continuous variables. If significant, we continued with 
pairwise tests (chi-square or Student’s t test). A multiple 
linear regression with simultaneous entry of variables 
was used to examine how the health and support vari-
ables were associated with QoL. We also controlled for 
demographic variables in this analysis. Results have been 
presented with standardized and non-standardized beta 
coefficients (β) with 95% confidence intervals (CIs). The 
adjusted R square  (R2) value assessed the percentage of 
the variation in QoL explained by the model. Prelimi-
nary analyses were undertaken to check for multicol-
linearity among the independent variables. None of the 
included variables had a Variable Inflation Factor (VIF) 
value higher than the recommended cut-off, i.e.,  ≤  3 (all 
VIF values were below 2.1) [37, p. 316]. The significance 
level was set at p  <  0.05. We used IBM SPSS version 25 
for analyses [38].
Results
Patients (N  =  518) had a mean age of 38 years and 69% 
were female (Table  1). The SUD and MD group were 
7 years younger (35 versus 42 years) and had a substan-
tially lower educational level than the PD group. The 
same trend applied to occupation and income, with sub-
stantially lower occupational levels and incomes than 
the PD patients. The educational level and income were 
especially low in the SUD group, with only 17% having 
education above the high school level and with 60% lower 
income than the PD group. Only four of ten in the SUD 
group were women, while the majority in the two other 
groups, approximately eight of ten, were female (Table 1).
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Family cohesion and social support
Related to the main aim of the study, the SUD and MD 
groups rated their family cohesion and social support 
to be significantly lower than the PD group (Table  2). 
A substantially higher proportion were living with-
out a current partner; 38% and 26% in the SUD and 
MD group, respectively, versus only 13% in the PD 
sample. Compared with the PD sample, the SUD and 
MD groups had, respectively, 4.0- and 2.6-point lower 
scores on the family cohesion scale. The perceived 
social support score (ISEL) was a substantial  ~  4 points 
lower in the SUD and MD groups compared with the 
PD sample (Table 2).
Health variables and QoL
Concerning health variables, the proportion with prob-
lematic substance use was much higher in the SUD 
group; 56% versus 14% and 3% in the other two groups 
(Table 2). Perceived mental distress was much higher in 
the MD group versus the two other groups, and the MD 
group had a mean score considerably above the clinical 
cut-off. The majority of the PD sample and the MD group 
reported uncertainty about the future (82% and 73% 
respectively), while a minority (35%) did in the SUD sam-
ple. In contrast, the longevity of the illness was greatest 
among the patients with SUDs: 13.0 years compared with 
10.3 and 4.5 years in the MD and PD groups, respectively 
(Table 2).
Table 1 Characteristics of participants (N  =  518)
PD physical disorders group; MD mental disorders group; SUD substance use disorder group; SD standard deviation, IQR interquartile range
a Proportion with at least some work/school occupation
b Income in 1.000 Norwegian currency; kroner (NOK)
Variables PD N  =  195 MD N  =  194 SUD N  =  129 Total N  =  518
Age, years, mean (SD) 42 (7) 35 (9) 35 (8) 38 (8)
Gender, women, N (%) 143 (73) 162 (84) 53 (41) 358 (69)
Educational level, N (%)
 Primary education 20 (10) 30 (16) 52 (40)
 High school 69 (35) 97 (50) 55 (43) 221 (43)
 College/university 106 (54) 67 (35) 22 (17) 195 (38)
Work or  studyinga, N (%) 117 (60) 79 (41) 52 (40) 248 (48)
Incomeb, mean (SD) 930 (1064) 599 (626) 383 (243) 670 (796)
Treatment duration, months, median 
(IQR)
8 (4–36) 16 (5–48) 19 (6–41) 13 (5–42)
Table 2 Family and social support, health variables and QoL (N  =  518)
PD physical disorders group, MD mental disorders group, SUD substance use disorder group
a Overall p value for difference between groups obtained from the chi-square test for categorical and ANOVA test for continuous variables
b p value for pair-wise tests were obtained from the chi-square test or Student’s t test
c Family cohesion was measured with the Family Adaptability and Cohesion Evaluation Scales (FACES-III)
d Social support was measured with the Interpersonal Support Evaluation List (ISEL)
e Problematic substance use was measured with the CAGE-AID
f Mental distress was measured with the Hopkin’s Symptom Check List-10—score 1–4
g Quality of Life was measured with the QoL-5, score 0.1–0.9
Variables PD N  =  195 MD N  =  194 SUD N  =  129 p  valuea PD/MDb PD/SUDb MD/SUDb
No partner, N (%) 25 (13) 57 (29) 49 (38) < 0.001 < 0.001 < 0.001 ns
Family cohesion sum  scorec, mean (SD) 42.8 (5.8) 40.2 (7.8) 38.8 (8.9) < 0.001 < 0.001 < 0.001 ns
Social support sum  scored, mean (SD) 40.1 (6.7) 35.5 (7.4) 36.1 (7.3) < 0.001 < 0.001 < 0.001 ns
Problematic substance  usee (in lifetime), N (%) 6 (3) 27 (14) 72 (56) < 0.001 < 0.001 < 0.001 < 0.001
Mental  distressf, mean (SD) 1.71 (0.58) 2.45 (0.74) 1.89 (0.71) < 0.001 < 0.001 < 0.05 < 0.001
Future uncertainty about the illness, N (%) 160 (82) 141 (73) 45 (35) < 0.001 < 0.05 < 0.001 < 0.001
Duration of the illness (years), mean (SD) 4.5 (9.7) 10.3 (9.9) 13.0 (11.5) < 0.001 < 0.001 < 0.001 < 0.05
Quality of life (QoL)g, mean (SD) 0.66 (0.14) 0.50 (0.16) 0.62 (0.17) < 0.001 < 0.001 < 0.05 < 0.001
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Only the MD group had a mean QoL score in the mark-
edly low range (0.50; Table  2). When reporting QoL in 
detail, the PD group rated their physical QoL as markedly 
reduced (0.52), but otherwise they had normal or near-
to-normal QoL scores (Fig. 1). Except for physical QoL, 
the SUD group rated their QoL as somewhat lower com-
pared with the PD patients, but still in the near-to-nor-
mal range. In the MD group, however, QoL was markedly 
lower compared with the other two groups, especially for 
ratings of psychological and existential QoL (0.43, Fig. 1). 
The MD sample even rated their physical QoL on a simi-
larly low level as those admitted for PDs.
Associations with QoL
Unexpectedly, treatment domain did not surface as a 
significant explanatory factor for variation in QoL in 
the multiple regression analysis (Table  3), indicating 
that factors across treatment domains are more relevant 
to explain variation in QoL. Only three variables were 
significantly associated with QoL. Higher social sup-
port (beta 0.05, 95% CI 0.03/0.06, p  <  0.001) and family 
cohesion (beta 0.03, 95% CI 0.02/0.04, p  <  0.001) were 
positively associated with QoL. Mental distress was 
negatively associated with QoL: beta −  0.15 (95% CI 
−  0.17/−  0.14, p  <  0.001), and was the strongest influ-
encing factor as evidenced by the highest standardized 
beta (Table 3). The model explained 65% of the variation 
in QoL.
Discussion
Family cohesion was lowest in the SUD and MD groups, 
and these two groups also rated their social support at a 
similarly low level, substantially lower than did the PD 
sample. The QoL score of the MD group was markedly 
lower than in the PD sample. In contrast, the SUD sample 
exhibited a somewhat lower QoL than did the PD sample, 
but their QoL was still above the cut-off for a markedly 
low QoL. When examining factors associated with QoL, 
Fig. 1 Comparison of scores on each QoL item of the QoL‑5 measure across groups. Notes: the overall p value was  <  0.001 for all constructs 
(ANOVA test). p values from pair‑wise tests were obtained using Student’s t test. *  ≤  0.05, **  ≤  0.001, Ns. not significant. Blue column  =  physical 
disorders group. Orange column  =  mental disorders group. Grey column  =  substance use disorder group. Green line  =  population mean
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mental distress came out as the strongest factor, and was 
negatively related to QoL.
A main aim of this study was to determine differences 
between patients with SUDs compared to MDs and 
PDs in their perceptions of family cohesion, social sup-
port, and QoL. While family and extended social sup-
port networks can be helpful in improving substance 
use outcomes, reducing mental distress, and support-
ing recovery [15, 39], it is thought that the longer-term 
strain and broken relationships might ‘test’ the ongoing 
level of support from the family and/or social network 
[9, 10]. The current data support this notion, with lower 
levels of family cohesion and social support for the MD 
and SUD groups. The strain and broken relationships 
might be illustrated in the current data with significantly 
longer duration of the illness (approximately three times 
longer for the SUD group compared with the PD group) 
and more patients in the SUD and MD groups having no 
partner. It has been observed that SUDs in a family have a 
disruptive effect on the functioning of a family and, as the 
illness progresses, it is followed by a decline in the quality 
of family relationships [10]. For a patient with an SUD, 
this is doubly lamentable, as it means that positive famil-
ial restraining influences may no longer be present and 
there may be a lack of motivational support to promote 
necessary behavioral changes in the patient.
As expected, we observed more problematic substance 
abuse in the SUD group, higher mental distress in the MD 
group, and lower physical QoL score ratings for the PD 
group. Unexpectedly, the SUD group exhibited near-to-
normal physical health, while there was a very low physi-
cal health rating in the MD group, equally low as in the 
PD group, as represented by the physical QoL score. Low 
patient-reported rating of physical health among persons 
with MDs has also been observed in previous research. A 
large European study found that patients with many cat-
egories of mental disorders, for example, dysthymia, any 
mood disorders and post-traumatic stress disorder, rated 
their physical health on a similarly low level as people 
with chronic physical diseases like diabetes, lung disease, 
and arthritis [40]. Physical health ratings in SUD treat-
ment studies are inconsistent. A large European epide-
miological study found near-to-normal reported physical 
health among patients with SUDs [40], while a previous 
Norwegian study of patients with severe SUDs admitted 
to a detoxification (detox) center reported similarly low 
physical health among patients with SUDs as inpatients 
admitted to a general medical ward [23]. The patients 
with SUDs in that study had also low physical health rat-
ings similar to the MD group of the present study. Thus, 
it is likely that the severity level of the SUD will influence 
rating of physical health.
The overall QoL score of the SUD group was close to 
the normal range and was only slightly lower than that 
seen in the PD group. This is unexpected in light of pre-
vious studies reporting substantially lower QoL among 
patients with SUDs compared with normative popula-
tions and compared with patients admitted to general 
Table 3 Factors associated with QoL (N  =  518)
FACES Family Adaptability and Cohesion Evaluation Scales; ISEL Interpersonal Support Evaluation List
a In this analysis, we used the mean scores of FACES and ISEL to facilitate interpretation
Beta (95% CI)b Standardized beta p
Sociodemographic variables
 Patient group 0.00 (− 0.02/0.02) 0 0.918
 Gender 0.00 (− 0.02/0.02) 0.01 0.709
 Age 0.00 (0.00/0.00) − 0.01 0.619
 Education 0.00 (− 0.01/0.01) 0 0.912
 Having a partner 0.00 (− 0.02/0.02) − 0.01 0.808
 Work or studying 0.01 (− 0.01/0.03) 0.03 0.291
 Income 0.00 (0.00/0.00) − 0.03 0.336
Social support  variablesa
 Social support (ISEL) 0.05 (0.03/0.06) 0.17 < 0.001
 Family cohesion (FACES) 0.03 (0.02/0.04) 0.13 < 0.001
Health and treatment variables
 Duration of the illness 0.00 (0.00/0.00) 0.03 0.313
 Uncertainty about the future − 0.02 (− 0.04/0.01) − 0.04 0.171
 Treatment duration 0.00 (0.00/0.00) 0.04 0.192
 Problematic substance use 0.00 (− 0.02/0.03) 0.01 0.871
 Mental distress − 0.15 (− 0.17/− 0.14) − 0.68 < 0.001
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medical wards [23, 24, 41]. The relatively high QoL level 
in the SUD group is also puzzling in light of the familial 
and social strain reported by this group. In contrast, the 
MD group reported a markedly low QoL, which repre-
sented a clinically significant reduction in QoL according 
to the interpretative guidelines [35]. We note here that 
the present respondents had already been in treatment 
for a substantial period (median 19 and 16  months for 
the SUD and MD group, respectively). Although we do 
not have data from their treatment admission, it is pos-
sible that their QoL has improved more with time than 
that of the MD group or, alternatively, that the MD group 
started at an even lower QoL at admission.
When examining associations with QoL, we found 
that family cohesion and social support related positively 
to QoL, as hypothesized, while elevated mental distress 
was negatively and strongly related to QoL: a one-point 
higher mental distress score resulted in a substantial 0.15 
lower QoL score. From a predictive perspective, previ-
ous studies of SUD treatment have found that worse 
mental health at baseline also predicted worse QoL at 
a later follow-up [42]. Seen from the perspective of the 
patients with SUDs, it is important to pay attention also 
to their mental health, as it is widely accepted that an 
SUD combined with a comorbid MD and/or elevated lev-
els of mental distress can have a negative impact on the 
patient’s condition and functioning [43]. Thus, although 
the mean level of mental distress among the SUD group 
in the present study was only slightly above the clinical 
cut-off, it is important to also follow up on their mental 
health [44].
Based on our study, we propose further research on 
family cohesion and social support in families with paren-
tal substance use disorder. We specifically recommend 
developing models for clinical support and guidance for 
families related to better family cohesion and increased 
social support. Furthermore, we recommend implemen-
tation studies with fidelity- and effect measurements.
Methodological considerations
The usual caveat about the interpretation of causality in 
cross-sectional research must be kept in mind: using this 
design, we cannot determine whether the independent 
variables caused the variation in QoL. The inclusion of 
patients was based on the treatment service the patient 
was admitted to, not on their diagnosis. Thus, we can-
not rule out that some patients might have had diagnoses 
that would make them eligible for inclusion in another 
patient group.
There are some indications in the data that could lead 
to speculation about whether the SUD group consisted of 
patients with a less severe SUD. These include the rela-
tively high QoL score and the fact that the CAGE-AID 
detected only 6 of 10 in the SUD group as having an 
SUD. There was also a low proportion of the SUD group 
who reported uncertainty about the future development 
of the condition. However, the longevity of the SUD 
patients’ problems argues against their having less severe 
SUDs. There is also a health system argument against the 
assumption of a mild SUD: to get access to specialized 
SUD treatment services in Norway, one has to present 
with at least a moderately severe SUD. The unexpect-
edly high QoL in the SUD group might be related to the 
assessment being performed in the midst of a treatment 
period combined with the relatively high optimism in the 
SUD group. The latter might indicate that this group had 
higher prognostic optimism than patients with MDs or 
PDs. Being in SUD treatment may have brought about a 
higher expectation of improvement and hope of recov-
ery than in the other two groups. Alternatively, there 
might have been different selection bias across groups. 
The research assistant indicated that the families with 
the most difficult and challenging care situation were 
less likely to participate and this was more noticeable for 
patients and families recruited from the MD and SUD 
treatment units. Thus, the differences between patient 
groups would have been even larger in disfavour of the 
MD and SUD groups if this selection bias could have 
been avoided.
Conclusions
The present study puts social support and family cohe-
sion in the SUD treatment field into perspective when 
compared with other treatment fields. When having an 
SUD, it is vital to build and maintain positive relation-
ships to protect oneself from the influences of negative 
relationships [45]. To improve outcomes for patients with 
an SUD, it is important to be aware of the weaker net-
work and less regulatory family and/or social support 
available to these patients. Service providers therefore 
need to have a consistent focus on the social networks of 
patients and include their families in treatment processes.
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